DZNep

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: DZNep
• 英文别名: 5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
• 化学式: C₁₂H₁₄N₄O₃
• 分子量: 262.26
• InChiKey: OMKHWTRUYNAGFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Methods for cancer therapy and stem cell modulation
  申请人：Agency for Science, Technology and Research

  公开号：EP2522352A1

  公开（公告）日：2012-11-14

  The present invention relates to a method of modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method comprises administering to the respective cell a compound of the general formula (I) In the general formula A is C or N. R1, R4 and R5 are, independently selected, H or aliphatic, cycloaliphatic, aromatic, arylaliphatic, or arylcycloaliphatic hydrocarbyl groups, that comprise 0 - 3 heteroatoms being N, O, S, or Si. R4 and R5 may optionally be linked so as to define an aliphatic hydrocarbyl bridge. R2 is H or a halogen, such as F or Cl. R3 is H, or an aliphatic or arylaliphatic hydrocarbyl group comprising 1 - 8 main chain carbon atoms and 0 - 3 heteroatoms being N, O, S, Si, or a halogen such as Cl or F. Also provided is a method for modulating gene expression in a cell that expresses the components of a polycomb repressive complex.

  本发明涉及一种调节干细胞/祖细胞多能性和/或自我更新特性的方法。该方法包括向各细胞施用通式(I)化合物 在通式中，A 是 C 或 N。R1、R4 和 R5 独立地选自 H 或脂肪族、环脂族、芳香族、芳脂族或芳环脂族烃基，其中包括 0 - 3 个杂质原子 N、O、S 或 Si。R4 和 R5 可选择性地连接，以形成脂族烃桥。R2 是 H 或卤素，如 F 或 Cl。R3 是 H，或脂肪族或芳脂族烃基，包括 1 - 8 个主链碳原子和 0 - 3 个 N、O、S、Si 或卤素（如 Cl 或 F）杂原子。 还提供了一种调节表达多聚抑制复合体成分的细胞中基因表达的方法。
• METHODS FOR CANCER THERAPY AND STEM CELL MODULATION
  申请人：Agency for Science, Technology and Research

  公开号：EP1993553B1

  公开（公告）日：2013-05-08
• METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR
  申请人：Agency for Science, Technology And Research

  公开号：EP2217240A1

  公开（公告）日：2010-08-18
• Methods for stem cells modulation
  申请人：Agency for Science, Technology and Research

  公开号：EP2522352B1

  公开（公告）日：2017-01-11
• METHOD OF INHIBITING FIBROGENESIS AND TREATING FIBROTIC DISEASE
  申请人：Mann Jelena

  公开号：US20120014962A1

  公开（公告）日：2012-01-19

  The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and/or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention.